NASDAQ:MIST

Milestone Pharmaceuticals (MIST) Stock Forecast, Price & News

$3.00

0.00 (0.00%)

(As of 09/25/2023 ET)

Compare

Today's Range: $3.00
▼
$3.07
50-Day Range: $2.68
▼
$3.47
52-Week Range: $2.68
▼
$9.73

Volume: 21,007 shs
Average Volume: 127,931 shs
Market Capitalization: $100.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Milestone Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 366.7% Upside
$14.00 Price Target
Short Interest: Healthy
1.54% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.48) to ($1.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

516th out of 962 stocks

Pharmaceutical Preparations Industry

229th out of 449 stocks

3.3

Analyst's Opinion

Consensus Rating
Milestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, Milestone Pharmaceuticals has a forecasted upside of 366.7% from its current price of $3.00.
Amount of Analyst Coverage
Milestone Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.54% of the outstanding shares of Milestone Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Milestone Pharmaceuticals has recently decreased by 45.40%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Milestone Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Milestone Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MIST.

N/A

News and Social Media Coverage

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.40% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.32% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($1.48) to ($1.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Milestone Pharmaceuticals is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Milestone Pharmaceuticals is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Milestone Pharmaceuticals has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

MIST Price History

30 days | 90 days | 365 days | Advanced Chart

MIST Stock News Headlines

September 5, 2023 | finance.yahoo.com

Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 24, 2023 | msn.com

Royalty Pharma and Ferring Pharmaceuticals enter $500M royalty agreement

September 25, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 11, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)

August 10, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

July 6, 2023 | msn.com

Milestone Pharmaceuticals (MIST) Price Target Decreased by 5.33% to 14.48

June 20, 2023 | msn.com

Jefferies Downgrades Milestone Pharmaceuticals (MIST)

June 20, 2023 | markets.businessinsider.com

Analyst Expectations for Milestone Pharmaceuticals's Future

September 25, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

June 20, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

June 10, 2023 | finance.yahoo.com

Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38%

May 23, 2023 | markets.businessinsider.com

Expert Ratings for Milestone Pharmaceuticals

May 22, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

May 16, 2023 | msn.com

HC Wainwright & Co. Reiterates Milestone Pharmaceuticals (MIST) Buy Recommendation

May 15, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)

May 12, 2023 | msn.com

Milestone Pharmaceuticals: Q1 Earnings Insights

May 11, 2023 | finanznachrichten.de

Milestone Pharmaceuticals, Inc.: Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

May 11, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

May 8, 2023 | finance.yahoo.com

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

May 1, 2023 | finance.yahoo.com

Lorenz Muller Is The Chief Commercial Officer of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) And They Just Picked Up 23% More Shares

April 21, 2023 | msn.com

Unusual Call Option Trade in Milestone Pharmaceuticals (MIST) Worth $14.46K

April 21, 2023 | finance.yahoo.com

Milestone Pharmaceuticals' (NASDAQ:MIST) investors will be pleased with their decent 75% return over the last three years

April 13, 2023 | nasdaq.com

Oppenheimer Maintains Milestone Pharmaceuticals (MIST) Outperform Recommendation

April 12, 2023 | finance.yahoo.com

Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

March 31, 2023 | finance.yahoo.com

Despite recent gains, Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insiders are still down US$91k after purchasing last year

March 30, 2023 | msn.com

Milestone Pharmaceuticals's Return On Capital Employed Overview

March 29, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update

See More Headlines

Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIST Company Calendar

Last Earnings: 8/10/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MIST
CUSIP: N/A
CIK: 1408443
Web: www.milestonepharma.com
Phone: (514) 336-0444
Fax: N/A
Employees: 39
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +363.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,390,000.00
Net Margins: N/A
Pretax Margin: -978.77%
Return on Equity: -98.76%
Return on Assets: -63.77%

Debt

Debt-to-Equity Ratio: 1.19
Current Ratio: 13.89
Quick Ratio: 13.89

Sales & Book Value

Annual Sales: $6 million
Price / Sales: 16.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.94 per share
Price / Book: 1.56

Miscellaneous

Outstanding Shares: 33,383,000
Free Float: 29,911,000
Market Cap: $100.82 million
Optionable: Not Optionable
Beta: 1.90

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Joseph G. Oliveto M.B.A. (Age 55)
CEO, Pres & Director
Comp: $905.71k

Mr. Amit Hasija (Age 50)
CFO & Exec. VP of Corp. Devel.
Comp: $603.18k

Dr. David B. Bharucha FACC (Age 61)
M.D., Ph.D., Chief Medical Officer
Comp: $440.67k

Dr. Philippe Douville M.B.A. (Age 61)
Ph.D., Founder, Strategic Advisor & Member of Scientific Advisory Board

Mr. Jeff Nelson (Age 42)
Chief Operating Officer

Mr. Roshan Girglani
VP of Marketing

Dr. Philip T. Sager FACC (Age 67)
FAHA, FHRS, M.D., Chief Medical Advisor & Member of the Scientific Advisory Board

Dr. Guy Rousseau
SVP of Regulatory Affairs and Quality Management

Ms. Anita Holz
VP & Head of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MIST Stock - Frequently Asked Questions

Should I buy or sell Milestone Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MIST shares.
View MIST analyst ratings or view top-rated stocks.
What is Milestone Pharmaceuticals' stock price forecast for 2023?: 3 analysts have issued 1-year price targets for Milestone Pharmaceuticals' shares. Their MIST share price forecasts range from $4.00 to $25.00. On average, they predict the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 363.6% from the stock's current price.
View analysts price targets for MIST or view top-rated stocks among Wall Street analysts.
How have MIST shares performed in 2023?: Milestone Pharmaceuticals' stock was trading at $3.96 at the start of the year. Since then, MIST stock has decreased by 23.7% and is now trading at $3.02.
View the best growth stocks for 2023 here.
Are investors shorting Milestone Pharmaceuticals?: Milestone Pharmaceuticals saw a drop in short interest in August. As of August 31st, there was short interest totaling 515,300 shares, a drop of 45.4% from the August 15th total of 943,800 shares. Based on an average daily trading volume, of 127,800 shares, the short-interest ratio is currently 4.0 days.
View Milestone Pharmaceuticals' Short Interest.
When is Milestone Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MIST earnings forecast.
How were Milestone Pharmaceuticals' earnings last quarter?: Milestone Pharmaceuticals Inc. (NASDAQ:MIST) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02.

What other stocks do shareholders of Milestone Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).
When did Milestone Pharmaceuticals IPO?: (MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
What is Milestone Pharmaceuticals' stock symbol?: Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."
Who are Milestone Pharmaceuticals' major shareholders?: Milestone Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.95%), Barclays PLC (2.40%), Barclays PLC (2.40%), Affinity Asset Advisors LLC (0.90%), BML Capital Management LLC (0.82%) and JPMorgan Chase & Co. (0.74%). Insiders that own company stock include David Bharucha, Debra K Liebert, Paul F Truex, Robert James Wills and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Milestone Pharmaceuticals?: Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Milestone Pharmaceuticals' stock price today?: One share of MIST stock can currently be purchased for approximately $3.02.
How much money does Milestone Pharmaceuticals make?: Milestone Pharmaceuticals (NASDAQ:MIST) has a market capitalization of $100.82 million and generates $6 million in revenue each year. The company earns $-58,390,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.
How can I contact Milestone Pharmaceuticals?: Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The official website for the company is www.milestonepharma.com. The company can be reached via phone at (514) 336-0444 or via email at ir@milestonepharma.com.

This page (NASDAQ:MIST) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial